CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Ramucirumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02069041
NCT02069041Phase 1Completed
CompareCT.gov

Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma

Eli Lilly and Company·interventional·Posted Feb 21, 2014·Updated Nov 21, 2018

In Brief

A Phase 1 clinical trial evaluating Ramucirumab and FOLFOX4 for Carcinoma, Hepatocellular. Completed, enrolled 8 participants across 3 sites.

Detailed Summary

The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesTaiwan
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 21, 2014
Enrollment StartApr 1, 2014
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.4 years ago

Interventions

Ramucirumabbiological

Administered IV.

FOLFOX4drug

Administered IV.